The terminal exams from 12/03/2013 will be held in decentralized pattern. Students can go to their usual class rooms at 8.30 am. Our staff members will conduct invigilation as per day order time table. All the classes will be conducted as per time table after exam hours. For any clarification pls contact HOD.
Exosome diagnostic tests could potentially detect and
monitor the progression of a wide variety of cancers. When treating other forms
of cancer, surgeons are able to biopsy tumors to diagnose and monitor the state
of the disease. For brain cancers like glioma, however, multiple biopsies can
be life threatening.Magnetic Resonance Imaging (MRI)
is a useful tool, tumors only show up on imaging scans once they are at least
one millimeter in diameter and comprise about 100,000
tumor cells.By that time, it may be too late for an early intervention.
On the flip side, MRIs can also yield false positives. Exosomes may be a
reliable method of screening for prostate cancer
as well. A PSA test is currently the most common, noninvasive means to screen
for prostate cancer in the U.S. PSA testing measures for elevated levels of
prostate-specific antigen, a protein produced by the prostate gland that is
used to liquefy semen in men.The higher a man’s PSA level, the more likely it
is that he has prostate cancer, says James McKiernan, director of urologic
oncology at Columbia University Medical Center. There are additional reasons,
however, for high PSA levels-and some men with prostate cancer do not always
have elevated PSA, he added.“Exosomes could be very
much [more] cancer specific. PSA might give you one specific biomarker
for cancer identification, but exosomes can give you an entire disease specific
profile so you would know whether or not it is a form of prostate cancer that
necessitates treatment.”Researchers at Exosome have developed a diagnostic kit
for prostate cancer with a diagnostic accuracy of around 75 percent-a rate
comparable with that of actually taking a tissue biopsy, says Wayne Comper, a
renal physiologist and chief science officer at Exosome. He says the first diagnostic kit could be available commercially by the
end of 2013.
Biocon
is the first and presently the leading biotech company in India. Initially it
brought in revenues by manufacturing enzymes. But it has gradually become more
research oriented with the goal of introducing new drugs to the market. Its
manufacturing capabilities include microbial and mammalian cell culture
fermentation, synthetic chemistry and therapeutic drugs for the treatment of
cancer, autoimmune and metabolic diseases.
Serum Institute of India
Serum
Institute of India, Indian Immunologicals and Bharat Biotech specialize in the
production of vaccines. Serum Institute of India is the world’s largest
producer of measles and DTP vaccines.
Panacea Biotec
Panacea
Biotec has recently set up a plant in Himachal Pradesh, India, for production
of bacterial and viral vaccines.
Nicholas Piramal
Wockhadrt Limited
Wockhardt
is a biopharma powerhouse with 11 world class manufacturing plants in India.
GlaxoSmithKline
Bharat Serum
Krebs Biochemicals and Industries Limited
Zydus Cadila
Indian Immunologicals
Shantha Biotechnics
Shantha
Biotechnics is located in Hyderabad and its products include Hepatitis B
vaccine, Streptokinase drug and Interferon alpha-2b.
Biological E
Mahyco Monsanto
MAHYCO
Monsanto has released a number of Bt cotton hybrids, which have been approved
for commercial cultivation. The significant reduction in the use of pesticides
and higher and better quality yields will result in increased incomes to
farmers. Genetically modified field crops like rice, mustard, groundnut, maize,
tubers like potato, vegetables like tomato, cabbage, okra, etc.,
